Biopsy-Validated Performance of Non-Invasive Tests for Preoperative Liver Assessment in Adults with Grade II–III Obesity Undergoing Metabolic Bariatric Surgery

INTRODUCTION: Metabolic dysfunction-associated steatotic liver disease (MASLD) with advanced liver fibrosis in metabolic bariatric surgery (MBS) candidates influences perioperative risk and management. The diagnostic performance of non-invasive liver tests (NITs) remains insufficiently validated in grade II-III obesity. We aimed to evaluate biopsy-validated diagnostic performance of liver NITs in this population. METHODS: Adults with grade II-III obesity and MASLD scheduled for MBS underwent preoperative vibration controlled elastography (VCTE) with controlled attenuated parameter (CAP) (Fibroscan®, Echosens, Fr), Fibrosis-4 index (FIB-4) and Fibroscan®-AST (FAST) score calculation and systematic intraoperative liver biopsy. Diagnostic performance was evaluated using receiver operating characteristic (AUROC) curve analysis and Youden index. RESULTS: Overall, 585 participants were included (BMI 44.7 ± 5.1 kg/m²; 40.8 ± 9.6 years, 87% female). Significant (≥F2) and advanced (≥F3) liver fibrosis prevalence was 6.3% and 3.9%. FIB-4 discrimination for ≥F3 was excellent (AUROC 0.91). An optimized cut-off of 1.07 yielded 96% sensitivity and 99.8% negative predictive value. VCTE showed an AUROC of 0.89 for ≥F3 with 97.8% success rate. For fibrosis ≥F3, using the cohort-derived FIB-4 threshold of 1.07 instead of 1.30 increased the sensitivity of sequential FIB-4/VCTE testing from 65.2% to 82.6%. CAP demonstrated good accuracy for steatosis detection (AUROC 0.80). FAST score was able to rule out at risk-MASH with negative predictive value over 97%. CONCLUSIONS: In this large grade II-III obesity cohort, FIB-4 and VCTE demonstrated high accuracy for ruling out advanced fibrosis. A lower FIB-4 threshold of 1.07 improved the sensitivity of sequential FIB-4/VCTE testing; however, external validation is required before its clinical implementation. CAP and FAST provided good performance for steatosis and at-risk MASH detection. These results may support the incorporation of NITs into the routine preoperative evaluation of MBS candidates, allowing identification of patients requiring specialized hepatology care. KEY POINTS: • Large biopsy-validated severe obesity cohort undergoing MBS. • FIB-4 showed excellent negative predictive value for advanced fibrosis. • FIB-4 cut-off 1.07 improved sensitivity for advanced fibrosis diagnosis. • VCTE showed strong accuracy for ≥F2 and ≥ F3 fibrosis detection.

Authors

Institutions

Publication Details

Journal
Obesity Surgery
Published
2026-11-18
DOI
https://doi.org/10.1007/s11695-026-09051-z
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Biopsy-Validated Performance of Non-Invasive Tests for Preoperative Liver Assessment in Adults with Grade II–III Obesity Undergoing Metabolic Bariatric Surgery

Thaís Guaraná de Andrade, Luís Fernando Ferreira, Fernando de Barros, Cristiane Valle Tovo et al.
3 links
Obesity Surgery
Liver Disease Diagnosis and Treatment
article

Biopsy-Validated Performance of Non-Invasive Tests for Preoperative Liver Assessment in Adults with Grade II–III Obesity Undergoing Metabolic Bariatric Surgery

Thaís Guaraná de Andrade, Luís Fernando Ferreira, Fernando de Barros, Cristiane Valle Tovo, Cristiane Alves Villela‐Nogueira, Carlos Frederico Ferreira Campos, Celso Didoné Filho, Claudia Ivantes, Leonardo Halamy
article en

Abstract

INTRODUCTION: Metabolic dysfunction-associated steatotic liver disease (MASLD) with advanced liver fibrosis in metabolic bariatric surgery (MBS) candidates influences perioperative risk and management. The diagnostic performance of non-invasive liver tests (NITs) remains insufficiently validated in grade II-III obesity. We aimed to evaluate biopsy-validated diagnostic performance of liver NITs in this population. METHODS: Adults with grade II-III obesity and MASLD scheduled for MBS underwent preoperative vibration controlled elastography (VCTE) with controlled attenuated parameter (CAP) (Fibroscan®, Echosens, Fr), Fibrosis-4 index (FIB-4) and Fibroscan®-AST (FAST) score calculation and systematic intraoperative liver biopsy. Diagnostic performance was evaluated using receiver operating characteristic (AUROC) curve analysis and Youden index. RESULTS: Overall, 585 participants were included (BMI 44.7 ± 5.1 kg/m²; 40.8 ± 9.6 years, 87% female). Significant (≥F2) and advanced (≥F3) liver fibrosis prevalence was 6.3% and 3.9%. FIB-4 discrimination for ≥F3 was excellent (AUROC 0.91). An optimized cut-off of 1.07 yielded 96% sensitivity and 99.8% negative predictive value. VCTE showed an AUROC of 0.89 for ≥F3 with 97.8% success rate. For fibrosis ≥F3, using the cohort-derived FIB-4 threshold of 1.07 instead of 1.30 increased the sensitivity of sequential FIB-4/VCTE testing from 65.2% to 82.6%. CAP demonstrated good accuracy for steatosis detection (AUROC 0.80). FAST score was able to rule out at risk-MASH with negative predictive value over 97%. CONCLUSIONS: In this large grade II-III obesity cohort, FIB-4 and VCTE demonstrated high accuracy for ruling out advanced fibrosis. A lower FIB-4 threshold of 1.07 improved the sensitivity of sequential FIB-4/VCTE testing; however, external validation is required before its clinical implementation. CAP and FAST provided good performance for steatosis and at-risk MASH detection. These results may support the incorporation of NITs into the routine preoperative evaluation of MBS candidates, allowing identification of patients requiring specialized hepatology care. KEY POINTS: • Large biopsy-validated severe obesity cohort undergoing MBS. • FIB-4 showed excellent negative predictive value for advanced fibrosis. • FIB-4 cut-off 1.07 improved sensitivity for advanced fibrosis diagnosis. • VCTE showed strong accuracy for ≥F2 and ≥ F3 fibrosis detection.

Obesity Surgery
Universidade Federal do Rio de Janeiro (BR), Universidade Federal de Ciências da Saúde de Porto Alegre (BR), Universidade Federal Fluminense (BR), Hospital Nossa Senhora das Graças (BR)
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro, Universidade Federal do Rio de Janeiro
Good health and well-being
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon